# Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy

> **NCT02856464** · PHASE2 · UNKNOWN · sponsor: **King's College Hospital NHS Trust** · enrollment: 124 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute

## Interventions

- **OTHER:** DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
- **OTHER:** DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice

## Key facts

- **NCT ID:** NCT02856464
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12-21
- **Primary completion:** 2020-09
- **Final completion:** 2020-09
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856464, "Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02856464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*